2 results
Approved WMORecruiting
Primary, improvement of the quality of life.Secondary, reduction of pain and a decrease of the number of treatments by a breast oedema therapist.
Approved WMOWill not start
To assess the safety and tolerability of ascending doses of PP-001 whenadministered as a single intravitreal injection from 0,3 *g, 0,6 *g and 1,2*g with the option of an addition cohort with a dose of 2,1 *g PP-001.To assess the efficacy of…